Oita, Japan

Tomonori Imayoshi


Average Co-Inventor Count = 4.3

ph-index = 5

Forward Citations = 69(Granted Patents)


Location History:

  • Nakatsu, JP (1988)
  • Oita, JP (1986 - 1989)
  • Fukuoka, JP (2000 - 2001)

Company Filing History:


Years Active: 1986-2001

Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovations of Tomonori Imayoshi

Introduction

Tomonori Imayoshi is a notable inventor based in Oita, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of topical preparations aimed at treating various medical conditions. With a total of 6 patents to his name, Imayoshi's work has had a meaningful impact on the industry.

Latest Patents

One of his latest patents involves an external preparation of 2-amino-2-(2-(4-octylphenyl)ethyl) propane-1,3-diol or pharmaceutically acceptable salts thereof for topical administration. This innovative formulation aims to inhibit rejection reactions during organ or bone marrow transplantation and to treat autoimmune diseases or allergic diseases. The active ingredient, 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol, is designed for effective topical administration.

Career Highlights

Throughout his career, Imayoshi has worked with prominent companies in the pharmaceutical sector, including Yoshitomi Pharmaceutical Industries, Ltd. and Welfide Corporation. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research and development.

Collaborations

Imayoshi has collaborated with esteemed colleagues such as Michio Terasawa and Tsuneo Fujii. These partnerships have fostered a collaborative environment that has led to innovative solutions in the pharmaceutical field.

Conclusion

Tomonori Imayoshi's contributions to pharmaceutical innovations demonstrate his commitment to improving medical treatments through his inventions. His work continues to influence the industry and offers hope for advancements in the treatment of various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…